Cette traduction est en cours de préparation. En attendant, nous affichons temporairement la version originale en anglais.
Entreprise · 08/06/20181 min de lecture
Development of Inhaled Antibacterial Drugs for Cystic Fibrosis and Non-Cystic Fibrosis Bronchiectasis; Public Workshop; Request for Comments
Traduction automatique locale · Langue originale de la source
Résumé
The Food and Drug Administration (FDA, the Agency, or we) is announcing the following public workshop entitled "Development of Inhaled Antibacterial Drugs for Cystic Fibrosis and Non-Cystic Fibrosis Bronchiectasis." The purpose of the public workshop is to discuss the clinical trial design challenges and future considerations for inhaled antibacterial products to treat cystic fibrosis (CF) and non-CF bronchiectasis.
Langue originale de la source: Federal Register — Food and Drug AdministrationOuvrir le communiqué original →